Is RBOT or NXGL more profitable?

Vicarious Surgical has a net margin of 0.00% compared to NexGel's net margin of -28.54%. NexGel's return on equity of -64.29% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Vicarious Surgical N/A -184.13% -112.50% NexGel -28.54% -64.29% -29.64%

Does the media favor RBOT or SONX?

In the previous week, Vicarious Surgical had 1 more articles in the media than Sonendo. MarketBeat recorded 2 mentions for Vicarious Surgical and 1 mentions for Sonendo. Sonendo's average media sentiment score of 0.75 beat Vicarious Surgical's score of -0.14 indicating that Sonendo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sonendo 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RBOT or ZYXI more profitable?

Vicarious Surgical has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Vicarious Surgical's return on equity of -184.13% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Vicarious Surgical N/A -184.13% -112.50% Zynex -68.35% -804.30% -36.67%

Which has stronger earnings & valuation, AMIX or RBOT?

Autonomix Medical is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Autonomix Medical N/A N/A -$16.72M -$74.58 N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is AMIX or RBOT more profitable?

Vicarious Surgical's return on equity of -184.13% beat Autonomix Medical's return on equity. Company Net Margins Return on Equity Return on Assets Autonomix Medical N/A -239.36% -192.46% Vicarious Surgical N/A -184.13% -112.50%

Does the media prefer AMIX or RBOT?

In the previous week, Autonomix Medical and Autonomix Medical both had 2 articles in the media. Autonomix Medical's average media sentiment score of 0.83 beat Vicarious Surgical's score of -0.14 indicating that Autonomix Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autonomix Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RBOT or GCTK?

Vicarious Surgical presently has a consensus target price of $7.00, indicating a potential upside of 4,027.36%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, research analysts plainly believe Vicarious Surgical is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, RBOT or GCTK?

Vicarious Surgical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A GlucoTrack N/A N/A -$19.39M -$18.04 N/A

Is RBOT or GCTK more profitable?

Vicarious Surgical's return on equity of -184.13% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Vicarious Surgical N/A -184.13% -112.50% GlucoTrack N/A -581.98% -220.10%

Does the media favor RBOT or GCTK?

In the previous week, GlucoTrack had 8 more articles in the media than Vicarious Surgical. MarketBeat recorded 10 mentions for GlucoTrack and 2 mentions for Vicarious Surgical. GlucoTrack's average media sentiment score of 0.14 beat Vicarious Surgical's score of -0.14 indicating that GlucoTrack is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GlucoTrack 0 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Vicarious Surgical (RBOT) Competitors

$0.17 0.00 (-0.24%)

As of 03:22 PM Eastern

Compare

RBOT vs. NXGL, SONX, ZYXI, AMIX, and GCTK

Should you buy Vicarious Surgical stock or one of its competitors? MarketBeat compares Vicarious Surgical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vicarious Surgical include NexGel (NXGL), Sonendo (SONX), Zynex (ZYXI), Autonomix Medical (AMIX), and GlucoTrack (GCTK). These companies are all part of the "medical equipment" industry.

How does Vicarious Surgical compare to NexGel?

Vicarious Surgical (NYSE:RBOT) and NexGel (NASDAQ:NXGL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

NexGel has higher revenue and earnings than Vicarious Surgical. NexGel is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
NexGel	$11.42M	0.35	-$3M	-$0.40	N/A

In the previous week, Vicarious Surgical had 2 more articles in the media than NexGel. MarketBeat recorded 2 mentions for Vicarious Surgical and 0 mentions for NexGel. NexGel's average media sentiment score of 0.00 beat Vicarious Surgical's score of -0.14 indicating that NexGel is being referred to more favorably in the news media.

Company	Overall Sentiment
Vicarious Surgical	Neutral
NexGel	Neutral

Vicarious Surgical has a net margin of 0.00% compared to NexGel's net margin of -28.54%. NexGel's return on equity of -64.29% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
NexGel	-28.54%	-64.29%	-29.64%

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 2.2% of NexGel shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by company insiders. Comparatively, 23.4% of NexGel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vicarious Surgical currently has a consensus price target of $7.00, suggesting a potential upside of 4,027.36%. NexGel has a consensus price target of $2.00, suggesting a potential upside of 359.45%. Given Vicarious Surgical's higher probable upside, equities research analysts clearly believe Vicarious Surgical is more favorable than NexGel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
NexGel	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vicarious Surgical has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, NexGel has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Summary

NexGel beats Vicarious Surgical on 9 of the 15 factors compared between the two stocks.

How does Vicarious Surgical compare to Sonendo?

Vicarious Surgical (NYSE:RBOT) and Sonendo (NYSE:SONX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Vicarious Surgical has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Sonendo has a beta of 1.86, indicating that its stock price is 86% more volatile than the broader market.

Vicarious Surgical has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Sonendo	-92.74%	-184.01%	-68.60%

Sonendo has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Sonendo	$44.40M	0.09	-$60.92M	-$71.12	N/A

Vicarious Surgical presently has a consensus target price of $7.00, suggesting a potential upside of 4,027.36%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vicarious Surgical is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 28.7% of Sonendo shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by insiders. Comparatively, 7.9% of Sonendo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Vicarious Surgical had 1 more articles in the media than Sonendo. MarketBeat recorded 2 mentions for Vicarious Surgical and 1 mentions for Sonendo. Sonendo's average media sentiment score of 0.75 beat Vicarious Surgical's score of -0.14 indicating that Sonendo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sonendo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vicarious Surgical beats Sonendo on 8 of the 14 factors compared between the two stocks.

How does Vicarious Surgical compare to Zynex?

Vicarious Surgical (NYSE:RBOT) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 29.7% of Zynex shares are held by institutional investors. 11.1% of Vicarious Surgical shares are held by insiders. Comparatively, 49.3% of Zynex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vicarious Surgical currently has a consensus price target of $7.00, suggesting a potential upside of 4,027.36%. Zynex has a consensus price target of $3.70, suggesting a potential upside of 2,860.00%. Given Vicarious Surgical's higher probable upside, equities research analysts plainly believe Vicarious Surgical is more favorable than Zynex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Zynex	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Zynex has higher revenue and earnings than Vicarious Surgical. Zynex is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A

In the previous week, Vicarious Surgical had 2 more articles in the media than Zynex. MarketBeat recorded 2 mentions for Vicarious Surgical and 0 mentions for Zynex. Zynex's average media sentiment score of 0.00 beat Vicarious Surgical's score of -0.14 indicating that Zynex is being referred to more favorably in the news media.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Zynex	Neutral

Vicarious Surgical has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Vicarious Surgical's return on equity of -184.13% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Zynex	-68.35%	-804.30%	-36.67%

Vicarious Surgical has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Zynex has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Summary

Zynex beats Vicarious Surgical on 8 of the 15 factors compared between the two stocks.

How does Vicarious Surgical compare to Autonomix Medical?

Autonomix Medical (NASDAQ:AMIX) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by company insiders. Comparatively, 11.1% of Vicarious Surgical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vicarious Surgical's return on equity of -184.13% beat Autonomix Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-239.36%	-192.46%
Vicarious Surgical	N/A	-184.13%	-112.50%

Autonomix Medical currently has a consensus target price of $42.00, suggesting a potential upside of 879.02%. Vicarious Surgical has a consensus target price of $7.00, suggesting a potential upside of 4,027.36%. Given Vicarious Surgical's higher probable upside, analysts plainly believe Vicarious Surgical is more favorable than Autonomix Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Autonomix Medical is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$16.72M	-$74.58	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Autonomix Medical has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

In the previous week, Autonomix Medical and Autonomix Medical both had 2 articles in the media. Autonomix Medical's average media sentiment score of 0.83 beat Vicarious Surgical's score of -0.14 indicating that Autonomix Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autonomix Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vicarious Surgical beats Autonomix Medical on 8 of the 12 factors compared between the two stocks.

How does Vicarious Surgical compare to GlucoTrack?

Vicarious Surgical (NYSE:RBOT) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Vicarious Surgical's return on equity of -184.13% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
GlucoTrack	N/A	-581.98%	-220.10%

Vicarious Surgical presently has a consensus target price of $7.00, indicating a potential upside of 4,027.36%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, research analysts plainly believe Vicarious Surgical is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by company insiders. Comparatively, 2.2% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, GlucoTrack had 8 more articles in the media than Vicarious Surgical. MarketBeat recorded 10 mentions for GlucoTrack and 2 mentions for Vicarious Surgical. GlucoTrack's average media sentiment score of 0.14 beat Vicarious Surgical's score of -0.14 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GlucoTrack	0 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vicarious Surgical has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Vicarious Surgical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

Summary

Vicarious Surgical beats GlucoTrack on 9 of the 12 factors compared between the two stocks.

Get Vicarious Surgical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RBOT vs. The Competition

Export

Metric	Vicarious Surgical	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.21M	$7.19B	$6.81B	$23.42B
Dividend Yield	N/A	1.32%	2.67%	4.15%
P/E Ratio	-0.02	49.84	27.00	30.95
Price / Sales	N/A	50.65	518.84	20.00
Price / Cash	N/A	26.91	26.68	18.81
Price / Book	0.02	6.94	10.67	4.76
Net Income	-$63.22M	$162.27M	$3.60B	$1.07B
7 Day Performance	2.79%	-1.23%	-0.37%	0.63%
1 Month Performance	-26.26%	-2.31%	1.85%	1.56%
1 Year Performance	-98.37%	5.51%	25.51%	17.80%

Vicarious Surgical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RBOT Vicarious Surgical	1.6377 of 5 stars	$0.17 -0.2%	$7.00 +4,027.4%	-98.4%	$1.21M	N/A	N/A	210	Gap Down
NXGL NexGel	2.2701 of 5 stars	$0.47 -0.5%	$2.00 +326.4%	-81.6%	$4.35M	$11.42M	N/A	10
SONX Sonendo	N/A	$0.82 +36.7%	N/A	N/A	$3.92M	$44.40M	N/A	250	Gap Up
ZYXI Zynex	N/A	$0.13 flat	$3.35 +2,580.0%	N/A	$3.80M	$108.20M	N/A	770
AMIX Autonomix Medical	3.5415 of 5 stars	$5.19 -9.7%	$42.00 +709.2%	-87.3%	$3.12M	N/A	N/A	1	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RBOT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vicarious Surgical (RBOT) Competitors

RBOT vs. NXGL, SONX, ZYXI, AMIX, and GCTK

How does Vicarious Surgical compare to NexGel?

Summary

How does Vicarious Surgical compare to Sonendo?

Summary

How does Vicarious Surgical compare to Zynex?

Summary

How does Vicarious Surgical compare to Autonomix Medical?

Summary

How does Vicarious Surgical compare to GlucoTrack?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vicarious Surgical (RBOT) Competitors

RBOT vs. NXGL, SONX, ZYXI, AMIX, and GCTK

How does Vicarious Surgical compare to NexGel?

Which has higher earnings and valuation, RBOT or NXGL?

Does the media refer more to RBOT or NXGL?

Is RBOT or NXGL more profitable?

Do insiders and institutionals hold more shares of RBOT or NXGL?

Do analysts recommend RBOT or NXGL?

Which has more risk & volatility, RBOT or NXGL?

Summary

How does Vicarious Surgical compare to Sonendo?

Which has more volatility & risk, RBOT or SONX?

Is RBOT or SONX more profitable?

Which has preferable earnings and valuation, RBOT or SONX?

Do analysts rate RBOT or SONX?

Do institutionals and insiders hold more shares of RBOT or SONX?

Does the media favor RBOT or SONX?

Summary

How does Vicarious Surgical compare to Zynex?

Do institutionals & insiders hold more shares of RBOT or ZYXI?

Do analysts prefer RBOT or ZYXI?

Which has preferable valuation & earnings, RBOT or ZYXI?

Does the media favor RBOT or ZYXI?

Is RBOT or ZYXI more profitable?

Which has more risk & volatility, RBOT or ZYXI?

Summary

How does Vicarious Surgical compare to Autonomix Medical?

Do institutionals and insiders have more ownership in AMIX or RBOT?

Is AMIX or RBOT more profitable?

Do analysts rate AMIX or RBOT?

Which has stronger earnings & valuation, AMIX or RBOT?

Which has more risk & volatility, AMIX or RBOT?

Does the media prefer AMIX or RBOT?

Summary

How does Vicarious Surgical compare to GlucoTrack?

Is RBOT or GCTK more profitable?

Do analysts recommend RBOT or GCTK?

Do institutionals & insiders believe in RBOT or GCTK?

Does the media favor RBOT or GCTK?

Which has more risk and volatility, RBOT or GCTK?

Which has better earnings & valuation, RBOT or GCTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools